-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with chronic kidney disease who have a reduced estimated glomerular filtration rate or increased proteinuria have an increased risk of ischemic and hemorrhagic stroke .
Stroke, medsci.
The researchers randomly assigned 4401 participants with type 2 diabetes and chronic kidney disease to the canalidrinet or placebo treatment group.
diabetes
142 participants experienced a stroke during the follow-up period (10.
There was no significant effect on AF/AFL (HR: 0.
There is evidence that the overall impact of SGLT2i on stroke varies with the baseline estimated glomerular filtration rate (P=0.
It can be seen that SGLT2i has no clear effect on overall stroke, but there is still some evidence that it has benefits in preventing hemorrhagic stroke and AF/AFL.
SGLT2i has no clear effect on overall stroke, but there is still some evidence that it has benefits in preventing hemorrhagic stroke and AF/AFL.
Original source:
Zien Zhou.